tiprankstipranks
Trending News
More News >
Agios Pharma (AGIO)
NASDAQ:AGIO

Agios Pharma (AGIO) Stock Statistics & Valuation Metrics

Compare
676 Followers

Total Valuation

Agios Pharma has a market cap or net worth of $1.63B. The enterprise value is $1.57B.
Market Cap$1.63B
Enterprise Value$1.57B

Share Statistics

Agios Pharma has 58,592,170 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding58,592,170
Owned by Insiders
Owned by Institutions

Financial Efficiency

Agios Pharma’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -38.18%.
Return on Equity (ROE)-0.35
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-38.18%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee111.17K
Profits Per Employee-849.34K
Employee Count486
Asset Turnover0.04
Inventory Turnover0.19

Valuation Ratios

The current PE Ratio of Agios Pharma is ―. Agios Pharma’s PEG ratio is 0.02.
PE Ratio
PS Ratio29.21
PB Ratio1.32
Price to Fair Value1.32
Price to FCF-4.18
Price to Operating Cash Flow-4.47
PEG Ratio0.02

Income Statement

In the last 12 months, Agios Pharma had revenue of 54.03M and earned -412.78M in profits. Earnings per share was -7.12.
Revenue54.03M
Gross Profit47.68M
Operating Income-472.13M
Pretax Income-413.80M
Net Income-412.78M
EBITDA-466.95M
Earnings Per Share (EPS)-7.12

Cash Flow

In the last 12 months, operating cash flow was -372.98M and capital expenditures -4.32M, giving a free cash flow of -377.29M billion.
Operating Cash Flow-372.98M
Free Cash Flow-377.29M
Free Cash Flow per Share-6.44

Dividends & Yields

Agios Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.96
52-Week Price Change-15.32%
50-Day Moving Average27.39
200-Day Moving Average34.05
Relative Strength Index (RSI)48.18
Average Volume (3m)847.20K

Important Dates

Agios Pharma upcoming earnings date is Apr 30, 2026, TBA (Confirmed).
Last Earnings DateFeb 12, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date

Financial Position

Agios Pharma as a current ratio of 11.46, with Debt / Equity ratio of 3.37%
Current Ratio11.46
Quick Ratio11.06
Debt to Market Cap0.03
Net Debt to EBITDA0.06
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Agios Pharma has paid -1.02M in taxes.
Income Tax-1.02M
Effective Tax Rate<0.01

Enterprise Valuation

Agios Pharma EV to EBITDA ratio is -3.32, with an EV/FCF ratio of -4.11.
EV to Sales28.71
EV to EBITDA-3.32
EV to Free Cash Flow-4.11
EV to Operating Cash Flow-4.16

Balance Sheet

Agios Pharma has $854.42M in cash and marketable securities with $40.21M in debt, giving a net cash position of $814.22M billion.
Cash & Marketable Securities$854.42M
Total Debt$40.21M
Net Cash$814.22M
Net Cash Per Share$13.90
Tangible Book Value Per Share$20.58

Margins

Gross margin is 88.26%, with operating margin of -873.87%, and net profit margin of -764.01%.
Gross Margin88.26%
Operating Margin-873.87%
Pretax Margin-765.89%
Net Profit Margin-764.01%
EBITDA Margin-864.28%
EBIT Margin-873.87%

Analyst Forecast

The average price target for Agios Pharma is $36.88, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$36.88
Price Target Upside33.82% Upside
Analyst ConsensusModerate Buy
Analyst Count9
Revenue Growth Forecast36.26%
EPS Growth Forecast-158.98%

Scores

Smart Score5
AI Score